

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11)

EP 0 938 899 A2



(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

01.09.1999 Bulletin 1999/35

(51) Int Cl. 6: A61K 31/70

(21) Application number: 98309544.9

(22) Date of filing: 23.11.1998

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 09.12.1997 JP 35405997

(71) Applicant: KABUSHIKI KAISHA HAYASHIBARA

SEIBUTSU KAGAKU KENKYUJO

Okayama-shi Okayama (JP)

(72) Inventors:

- Fukuda, Shigeharu
Okayama-shi, Okayama (JP)
- Miyake, Toshio
Okayama-shi, Okayama (JP)

(74) Representative: Daniels, Jeffrey Nicholas et al

Page White & Farrer
54 Doughty Street
London WC1N 2LS (GB)

(54) Agent for improving the blood circulation

(57) An agent for improving the blood circulation, which contains as an effective ingredient glycosyl vita-

min P such as glycosyl hesperidin and glycosyl rutin. The agent improves the blood circulation in humans to effectively relieve muscular rigidity.

EP 0 938 899 A2

Description

[0001] The present invention relates to an agent for improving the blood circulation, and more particularly to an agent for improving the blood circulation containing glycosyl vitamin P as an effective ingredient.

5 [0002] As means for communicating information and for drafting documents have become diversified, variety types of Office Automated (OA) instruments are widely spread in work places including offices, as well as homes in general. OA instruments generally require users a posture of detaching the users' upper arms from their bodies during operation to cause *STIFF* in particular parts of the limbs, arms, backs, waists, etc., as a result of muscular rigidity caused by the users' relatively-long-time operation of the instruments. Generally, *STIFF* in the muscular may be easily relieved by
10 grasping or massaging the stiff parts. However, in the case of operating OA instruments daily, if *STIFF* is once occurred, it could not be easily diminished. In addition to the operation of OA instruments, *STIFF* can be induced by factors such as physical exercise, physical labor, inappropriate posture, and mental stress or may be induced by diseases such as cervical spondylosis, thoracic outlet syndrome, hypertension, asthenopia, autonomic dystonia, and climacteric disturbance. Depending on the symptom of *STIFF*, particular slow pains and unpleasant feelings will last for a relatively-long
15 period of time, and in some cases *STIFF* may accompany head ache and/or vomiting.

15 [0003] Although the mechanism of occurrence of *STIFF* is still not clear, it is deemed that excessive stimulation of nerves, muscular fatigues, and autonomic dystonia will trigger successive contraction of peripheral veins, disorder of the blood circulation in muscular, and congestion, causing a specific *STIFF*. Therefore, improvement of the blood circulation is effective to diminish muscular *STIFF*. Treatments such as massage, warm bath therapy, fomentation, electric
20 stimulation, and administration are difficult to attain the desired effect, or some of them would be troublesome because patients should have to go hospitals for receiving professional treatments.

20 [0004] In view of the foregoing, the present invention aims to provide a dailyusable means for effectively improving the blood circulation with lesser side effects. The present inventors studied biologically active substances to solve the above object. As a result, they found that glycosyl vitamin P as a vitamin improves the blood circulation, resulting in
25 an effective exertion of a strong effect on relieving muscular rigidity induced by muscular stiffness in the shoulder and lumbago. They also found that the action of glycosyl vitamin P is significantly accelerated by trehalose, a disaccharide. Thus the present invention provides an agent for improving the blood circulation, which contains glycosyl vitamin P as an effective ingredient.

30 [0005] The glycosyl vitamin P used in the present invention is a known compound, and similarly as vitamin P it is known that the compound has an activity of inhibiting the permeability of capillaries. The present invention is based on an unexpected finding of the action by glycosyl vitamin P that improves the blood circulation in humans and relieves muscular rigidity independently of the inhibition of capillary permeability. The present invention is novel in that it provides a use of glycosyl vitamin P as an agent for improving the blood circulation.

35 [0006] The invention will now be described in further detail, by way of example only, with reference to the accompanying drawings, in which:-

[0007] FIG. 1 is a figure that shows an MV pattern detected from a volunteer's dorsum cucullaris just before a cataplasma containing glycosyl vitamin P was attached to the volunteer.

[0008] FIG. 2 is a figure that shows an MV pattern detected from a volunteer's dorsum cucullaris just after a cataplasma containing glycosyl vitamin P has been attached to the volunteer for about eight hours.

40

Detailed Description of the Invention

[0009] The present invention relates to an agent for improving the blood circulation, which contains glycosyl vitamin P as an effective ingredient. The glycosyl vitamin P used in the present invention usually includes glycosyl hesperidins such as a series of α -monoglucosyl hesperidin, α -diglucosyl hesperidin, α -triglucosyl hesperidin, α -tetraglucosyl hesperidin, and α -pentaglucosyl hesperidin; and glycosyl rutins such as a series of α -monoglucosyl rutin, α -diglucosyl rutin, α -triglucosyl rutin, α -tetraglucosyl rutin, and α -pentaglucosyl rutin. Since these compounds exert substantially the same level of activity of improving the blood circulation, the present agent should contain one or more of them in an effective amount in total. In this connection, glycosyl hesperidin is superior to glycosyl rutin when compared with their activity on relieving muscular rigidity accompanied by lumbagos and muscular pains and on treating diseases with muscular rigidity.

45 [0010] The glycosyl vitamin P can be prepared by different methods. With an economical viewpoint, biochemical methods using saccharide-transferring enzymes are advantageous; The aforesaid series of glycosyl vitamin P can be obtained in a relatively-high yield by contacting vitamin P such as hesperidin and rutin with saccharide-transferring
50 enzymes such as α -glucosidase, cyclomaltodextrin glucanotransferase, and α -amylase in the presence of α -glucosyl saccharides such as partial starch hydrolysates and maltooligosaccharides. The reaction products thus obtained usually contain a series of glycosyl vitamin P compounds with glucose polymerization degrees of 1-5 in terms of transferred glucoses. These compounds can be hydrolyzed into α -monoglucosyl vitamin P by the action of glucoamylase and

optionally in combination with rhamnosidase. Methods using saccharide-transferring enzymes are disclosed in detail in Japanese Patent Kokai Nos. 7,593/91, 27,293/91, 58,790/91, and 115,292/91 applied by the same applicant as the present invention; and Japanese Patent Application Nos. 104,272/97, 22,667/97, and 69,588/97 by the same applicant as the present invention. Examples of commercialized products prepared by these methods are " α G RUTIN", a powdery glycosyl rutin product with a total rutin content of 40-82%, on a dry solid basis (d.s.b.), commercialized by Hayashibara Shoji, Inc., Okayama, Japan; and " α G HESPERIDIN", a powdery glycosyl hesperidin product with a total hesperidin content of 22-84%, d.s.b., commercialized by Hayashibara Shoji, Inc., Okayama, Japan. The glycosyl vitamin P used in the present invention should not necessarily be in a highly-purified form or may be in the form of a composition unseparated from other specific substances inherent to the preparation methods used.

5 [0011] As described above, the activity of improving the blood circulation by glycosyl vitamin P is significantly augmented in the presence of trehalose, which trehalose also stabilizes the glycosyl vitamin P, facilitates the administration of the compound, and exerts an activity of promoting the absorption of the compound. Since there found no natural system where glycosyl vitamin P coexists with trehalose, the fact that trehalose promotes the effective activities of glycosyl vitamin P was nothing but a completely-unpredictable finding. The present embodiment, where the artificially-produced glycosyl vitamin P and trehalose are artificially combined, is quite novel in this point.

10 [0012] Explaining the trehalose advantageously used in the present invention, there found, as it is well known, three isomers called α , α -, α , β -, and β , β -isomers having different bonding forms. Since these isomers exert a similar promoting activity on glycosyl vitamin P, they can be used in the present agent for improving the blood circulation independently of their preparation, purity, and property as long as one or more of them are incorporated into the present agent in an effective amount in total.

15 [0013] Trehalose can be produced by a variety methods. Detailed descriptions of such methods are given up because this invention in itself does not relate thereunto. However, considering economical benefit, preferable methods are those which comprise of contacting partial starch hydrolysates with a non-reducing saccharide-forming enzyme and a trehalose-releasing enzyme as disclosed in Japanese Patent Kokai Nos. 143,876/95, 213,283/95, 322,883/95, 25 298,880/95, 66,187/96, 66,188/96, 336,388/96, and 84,586/96. According to these methods, α , α -trehalose can be produced from starches as costless materials in a relatively-high yield; Examples of commercialized products obtained thereby are "TREHAOSE®", a crystalline trehalose powder containing at least 98% trehalose, d.s.b., commercialized by Hayashibara Shoji, Inc., Okayama, Japan; and "TREHASTAR®", a trehalose syrup containing at least 28% trehalose, d.s.b., commercialized by Hayashibara Shoji, Inc., Okayama, Japan. α , α -Trehalose can be produced by contacting partial starch hydrolysates either with a maltose/trehalose converting enzyme as disclosed in Japanese Patent Kokai-Nos. 149,980/96 and 9,986/97 or with conventionally known maltose-and trehalose-phosphorylases in combination.

20 [0014] To produce α , β -trehalose, cyclomaltodextrin glucanotransferase and β -galactosidase are allowed in this order to contact with mixtures of partial starch hydrolysates and lactose according to the methods as disclosed in Japanese Patent Kokai Nos. 144,694/92 and 179,490/92 applied by the same applicant as the present invention. Similarly as glycosyl vitamin P, the trehalose used in the present invention should not necessarily be in a highly-purified form or may be in the form of a composition unseparated from other specific substances inherent to the preparation methods used. Depending on use, the present agent contains trehalose in an amount of at least five-fold higher, and preferably 50-fold or higher than that of glycosyl vitamin P, d.s.b.

25 [0015] The agent according to the present invention includes those which consist of glycosyl vitamin P and those in the form of compositions comprising glycosyl vitamin P and another ingredients which ease the administration of glycosyl vitamin P. The above compositions are usually commercialized in the form of a liquid, paste or solid food product or pharmaceutical. The agent in the form a food product can be prepared into a composition comprising materials and/or ingredients used generally in food products such as water, alcohols, amylaceous substances, fibres, saccharides, 30 lipids, vitamins, minerals, flavors, colors, sweeteners, seasonings, stabilizers, and preservatives. The agent in the form a pharmaceutical can be prepared into a composition comprising carriers, excipients, adjuvants, diluents, and stabilizers, and optionally one or more of other biologically active substances such as tocopherol, acetic retinol, pyridoxine hydrochloride, glycine, ethanol, nicotinamide, licorice extract, and extract of *Angelica acutiloba*. Independently of the aforementioned forms, the present agent usually contains at least 0.001 w/w % glycosyl vitamin P, and preferably 0.01-10 w/w %. As already explained, trehalose effectively facilitates the administration of glycosyl vitamin P.

35 [0016] Explaining the use of the present agent for improving the blood circulation, it exerts a remarkable activity of improving the blood circulation independently of the oral- and parenteral-administrations. Depending on use, in the case of maintaining and promoting health and preventing diseases, the present agent is usually administered orally in the form of a food product, while in the case of treating diseases and recovering health from unsatisfiable health conditions, the present agent is usually administered orally in the form of a pharmaceutical or food product, or administered parenterally in the form of an injection or external medicament. The dose of the present agent is about one milligram to about one gram per shot per adult, and preferably 10 mg to 10 g per shot per adult in terms of glycosyl vitamin P at an administration frequency of 1-4 shots/day or 1-5 shots/week.

[0017] Based on the following experiments the effect and toxicity of the present agent are described:

Experiment 1

5 Relaxation of muscular rigidity

[0018] A cataplasma containing glycosyl vitamin P was prepared and evaluated on the effect when administered to patient suffering from stiffness in the shoulder based on the basis of micro-vibration (hereinafter abbreviated as "MV") and plethysmogram or volume pulse wave (hereinafter abbreviated as "PTG"). MV is an apparatus for recording micro-vibration of ballistic components accompanied by muscular fibers *in vivo* and heartbeat by converting the micro-vibration into an electrodynamic phenomenon where peaks are detected at a high-frequency region in patients with muscular rigidity such as stiffness in the shoulder, and the peaks are shifted to a lower-frequency region as the muscular rigidity is relieved. PTG is an apparatus for detecting blood flow as a vascular change in pressure and for expressing change in volume as a wave-height level; When the wave-height level is increased as the increment of blood flow in a stiff part in the shoulder, meaning that blood circulation is improved. The judgement whether the administration of glycosyl vitamin P improved blood circulation and relieved muscular rigidity can be objectively evaluated by MV and PTG after the administration. The significance and measurement of MV and PTG are described in detail, for example, in *Bulletin of the University of Tsukuba, School for the Blind*, Vol. 16, pp. 75-83 (1983), and *"Rinsho-Kensa-Koza"* (Clinical Testing Course), Vol. 11, pp. 115-135 (1985), published by Ishiyaku Shuppan Publishers, Inc., Tokyo, Japan.

10 [0019] Explaining the particulars of the experiment, a 48-year-old male volunteer suffering from the stiffness in both shoulders was quietly lain face down on a bed after attaching pickups for detecting MV and PTG to a line of dorsum cucullaris with a surgical tape. The patient was monitored for both MV and PTG by a polygraph for 20 min, and the data were recorded by a data recorder. Thereafter, the patient was allowed to sleep well overnight for about eight hours after the pickups were removed from the patient, and either a cataplasma prepared by the method in the later described
15 25 Example 7 or a placebo as a control prepared similarly as above except for omitting glycosyl vitamin P was attached to the patient.

20 [0020] On the next morning, the cataplasma was removed from the volunteer while he was allowed to lay on the bed, followed by attaching pickups to the same part as of the cataplasma for measuring and recording MV and PTG for 30 min and for two hours, respectively, similarly as above. The measured and recorded MV and PTG were data processed
25 30 by a signal processor to determine the effectiveness of glycosyl vitamin P. The measurement of MV and PTG conducted were as follows: Using "MODEL MT-3T" and "MODEL 45261", which are respectively an MV and PTG pickups commercialized by NEC San-ei Instrument Ltd., Tokyo, Japan, the data obtained from "MODEL 97A", a polygraph commercialized by NEC San-ei Instrument Ltd., Tokyo, Japan, connected with the pickups, was first recorded by "MODEL XR-710", a data recorder commercialized by Teac Corporation, Tokyo, Japan, then appropriately data-processed with
35 45 "MODEL 7T18A", a signal processor commercialized by NEC San-ei Instrument Ltd., Tokyo, Japan, to determine MV pattern and PTG. The MV patterns before and after the attachment of a cataplasma, prepared by the method in later described Example 7, are respectively in FIGS. 1 and 2. The axis of ordinates in these figures means a relative value of voltage, obtained by appropriately amplifying the *in vivo* signals detected in the volunteer.

40 [0021] As shown in FIG. 1, the MV pattern before the attachment of the cataplasma exhibited a relatively-strong peak characteristic of muscular rigidity at a high frequency of around seven hertz, confirming that the volunteer was in a typical state of stiffness in the shoulder. However, as shown in FIG. 2, the MV pattern eight hours after the attachment
45 55 of the cataplasma containing glycosyl vitamin P exhibited substantially no high-frequency peak but in turn it exhibited a strong peak for a lower frequency of around four hertz characteristic of muscular relief. As not shown in figure, the MV pattern as a control still exhibited the peak characteristic of muscular rigidity even after an eight-hour-sound-sleep similarly as in FIG. 1. The result evidences that glycosyl vitamin P is effective for relieving muscular rigidity caused by stiffness in the shoulder.

50 [0022] Referring to PTG, it turned to be in the range from about 270% to about 300% after the experiment of eight-hour-attachment of the cataplasma containing glycosyl vitamin P. In the control where the placebo was attached, a similar PTG was still observed as just before the experiment even after an eight-hour-sound sleep. The change of PTG was successively observed for about two hours after the cataplasma containing glycosyl vitamin P was detached, revealing that if the blood circulation is once improved, the condition is satisfactorily kept at a relatively-high level through over the observation period. The results confirm that glycosyl vitamin P is effective for improving the blood circulation in humans and that the effect will last for a relatively-long period of time. Similar experiment on vitamin P substantially showed no remarkable effect as compared with control. The reason is that an effective amount of vitamin P was not absorbed by living bodies because of its relatively-low water-solubility.

Experiment 2Clinical test

5 [0023] Based on the data of Experiment 1, 60 male volunteers, ranging from 28 to 51 years old, who were suffering from lumbago or chronic stiffness in the shoulder, were subjected to a clinical experiment. Three groups, each of which consisted of 10 randomly-chosen-male-volunteers, were provided and treated with the following treatment for a week;
10 At every night before sleeping, the volunteers were attached with either a cataplasm as an embodiment No. 1 according to the present invention, prepared by the later described method in Example 7; a cataplasm as an embodiment No. 2 according to the present invention, similarly prepared by the method in Example 7 except for replacing trehalose with sucrose; or a placebo as a control similarly prepared by the method in Example 7 except for omitting glycosyl vitamin P, and then replacing the cataplasm with fresh one every following night before sleeping. A clinical paramedic conducted the experiment and, after the experiment, asked the therapeutic effect and the side effects of the volunteers. The therapeutic effect was evaluated with four ranks of "very effective", "effective", "unchanged", and "worsened", and
15 the effectivity (%) was calculated as a percentage of the number of volunteers, who answered "very effective" and "effective", to the total number of volunteers. The results are in Table 1.

20

25

30

35

40

45

50

55

Table 1

Answer	Embodiment No. 1 according to the present invention	Embodiment No. 2 according to the present invention	Control
Very effective	2	1	0
Effective	4	4	2
Unchanged	3	4	7
Worsened	1	1	1
Effectivity (%)	60	50	20

Note: Embodiment Nos. 1 and 2 mean an agent for improving the blood circulation containing glycosyl vitamin P and trehalose according to the present invention, and an agent for improving the blood circulation containing glycosyl vitamin P according to the present invention, respectively.

[0024] In parallel three groups, each of which consisted of 10 volunteers who were randomly chosen from the resting 30 volunteers, were provided and orally administered every day and every meal for a week with three same tablets of either a tablet as an embodiment No. 3 according to the present invention, prepared by the later described method in Example 5; a tablet as an embodiment No. 4 similarly prepared by the method in Example 5 except for replacing trehalose with sucrose; or a tablet as a placebo similarly prepared by the method in Example 5 except for omitting glycosyl vitamin P. A clinical paramedic conducted the experiment and, at 24 hours after the final administration, asked the therapeutic effect and the side effects of the volunteers. The therapeutic effect was similarly evaluated as in the above criteria of four ranks. The results are in Table 2.

10

15

20

25

30

35

40

45

50

55

Table 2

Answer	Embodiment No. 3 according to the present invention	Embodiment No. 4 according to the present invention	Control
Very effective	1	1	0
Effective	4	3	1
Unchanged	5	5	9
Worsened	0	1	0
Effectivity (%)	50	40	10

Note: Embodiment Nos. 3 and 4 mean an agent for improving the blood circulation containing glycosyl vitamin P and trehalose according to the present invention, and an agent for improving the blood circulation containing glycosyl vitamin P according to the present invention, respectively.

[0025] The results in Tables 1 and 2 evidence that glycosyl vitamin P has an activity of effectively relieving muscular rigidity induced by lumbago and stiffness in the shoulder when administered to humans independently of its administration route with lesser side effects, and that the activity is significantly augmented by trehalose, a specific saccharide among various saccharides. Preliminary experiments on symptoms other than lumbago and stiffness in the shoulder revealed that glycosyl vitamin P exerts a strong effect on muscular pains, neuralgias, sprains, feelings of cold, frostbites, bruises, arthritis, neuritis, tendovaginitis, asthenopia, arteriosclerosis, etc.

Experiment 3

10 Acute toxicity test

[0026] An adequate amount of "TREHAOSE®", a crystalline trehalose powder commercialized by Hayashibara Shoji, Inc., Okayama, Japan, was dissolved in physiological saline containing 5 w/w % gum arabic, and the solution was sterilized in usual manner and intraperitoneally injected to ddY-mice, 20-25 g weight, in a group of 10 mice, or orally administered to the mice by using a stomach sonde. Thereafter, the mice were observed for a week. As a result, no mouse died even administered with a dose of about 16 g per kg mouse as a maximum dose challenged, independently of its administration route. In parallel similar experiments were conducted using as glycosyl vitamin P "αG HESPERIDIN PA" with a total hesperidin content of 74-78%, d.s.b., a glycosyl hesperidin power commercialized by Hayashibara Shoji, Inc., Okayama, Japan, and "αG RUTIN PS" with a total rutin content of 80-82%, d.s.b., a glycosyl rutin powder commercialized by Hayashibara Shoji, Inc., Okayama, Japan. As a result, no mouse died up to a dose of about five grams per kg mouse as a maximum dose challenged.

[0027] The results in Experiments 1-3 evidence that the present agent for improving the blood circulation is effectively administered to humans with lesser side effects.

[0028] With reference to the following Examples, the preferred embodiments according to the present invention are described as follows:

Example 1

Health food

[0029] One hundred and fifty parts by weight of "TREHASTAR®", a trehalose syrup commercialized by Hayashibara Shoji, Inc., Okayama, Japan, was heated and concentrated *in vacuo* up to give a moisture content of about 15 w/w %. The concentrate was mixed with a solution obtained by dissolving 13 parts by weight of gelatin in 18 parts by weight of water, one part by weight of "αG HESPERIDIN H" with a total hesperidin content of 22-26%, a glycosyl hesperidin powder commercialized by Hayashibara Shoji, Inc., Okayama, Japan, two parts by weight of citric acid, and adequate amounts of a coloring agent and a flavor, and the resulting mixture was shaped and packed to obtain a gummy candy.

[0030] The product with a satisfactory texture and flavor is useful as a health food that improves/maintains the blood circulation to relieve and/or prevent muscular rigidity caused by lumbago, stiffness in the shoulder, muscular pains, etc.

40 Example 2

Health food

[0031] Three parts by weight of a gum base was melted by heating until softened, mixed with seven parts by weight of "NUMIX", a powdered green and yellow vegetable with a trehalose content of about 50 w/w %, commercialized by H+B Life Science Co., Ltd., Okayama, Japan; adequate amounts of a coloring agent and a flavor; and "αG RUTIN P", a glycosyl rutin powder with a total rutin content of 40-46%, d.s.b., in an amount sufficient to be brought up to a content of 0.1%, d.s.b., and the resulting mixture was in usual manner kneaded, shaped, and packed to obtain a chewing gum containing glycosyl vitamin P.

[0032] The product with a satisfactory texture and taste is useful as a health food that improves/maintains the blood circulation to relieve and/or prevent muscular rigidity caused by lumbago, stiffness in the shoulder, muscular pains, etc.

Example 3

55 Health food

[0033] Eighty-six parts by weight of skim milk, three parts by weight of skim milk powder, nine parts by weight of "TREHASTAR®", a trehalose syrup commercialized by Hayashibara Shoji, Inc., Okayama, Japan, 0.1 part by weight

of agar, 0.1 part by weight of " α G HESPERIDIN PA", a glycosyl hesperidin powder with a total hesperidin content of 74-78%, d.s.b., commercialized by Hayashibara Shoji, Inc., Okayama, Japan, and 1.8 parts by weight of water were placed in a tank and heated to 55°C to completely dissolve the contents under stirring conditions. Thereafter, the mixture was homogenized in usual manner, sterilized by a sterilizing cooler, inoculated with three w/w % of a starter, injected into a plastic container, and fermented at 37°C for five hours into a yogurt containing glycosyl vitamin P.

[0034] The product with a satisfactory flavor and taste is useful as a health food that improves/maintains the blood circulation to relieve or prevent muscular rigidity caused by lumbago, stiffness in the shoulder, muscular pains, etc.

Example 4

Supplemental health food

[0035] One part by weight of " α G HESPERIDIN PA", a glycosyl hesperidin powder with a total hesperidin content of 74-78%, d.s.b., commercialized by Hayashibara Shoji, Inc., Okayama, Japan, and 99 parts by weight of "TREHAOSE®", a crystalline trehalose powder commercialized by Hayashibara Shoji, Inc., Okayama, Japan, were mixed to homogeneity, and 50 g aliquots of the resulting mixture were injected into glass vials to obtain the desired product.

[0036] About one gram of the product is spooned up for eating directly or for drinking after dissolved in water for ease of a supplement of about 10 mg glycosyl vitamin P to the body. The product with a superior solubility and handleability is useful as a supplementary health food that improves/maintains the blood circulation to relieve and/or prevent muscular rigidity caused by lumbago, stiffness in the shoulder, muscular pains, etc.

Example 5

Tablet

[0037] Ten parts by weight of "AA-2G", a glycosyl vitamin C powder commercialized by Hayashibara Shoji, Inc., Okayama, Japan, three parts by weight of " α G HESPERIDIN PA", a glycosyl hesperidin powder with a total hesperidin content of 74-78%, d.s.b., commercialized by Hayashibara Shoji, Inc., Okayama, Japan, and 17 parts by weight of "TREHAOSE®", a crystalline trehalose powder commercialized by Hayashibara Shoji, Inc., Okayama, Japan, were mixed to homogeneity. The mixture was tabletted in usual manner to obtain a tablet containing 10 mg glycosyl vitamin P.

[0038] The product, having a readily swallowability and solubility and a vitamin C-supplementing action, is useful as a tablet that improves/maintains the blood circulation to relieve and/or prevent muscular rigidity caused by lumbago, stiffness in the shoulder, muscular pains, etc.

Example 6

Solution

[0039] In 1,000 parts by weight of distilled water were dissolved six parts by weight of sodium chloride, 0.3 part by weight of potassium chloride, 0.2 part by weight of calcium chloride, 3.1 parts by weight of sodium lactate, 44 parts by weight of "TREHAOSE®", a crystalline trehalose powder commercialized by Hayashibara Shoji, Inc., Okayama, Japan, 1.5 parts by weight of " α G HESPERIDIN PS", a glycosyl hesperidin powder with a total hesperidin content of 80-84%, d.s.b., commercialized by Hayashibara Shoji, Inc., Okayama, Japan, and 0.5 part by weight of "AA-2G®", a glycosyl vitamin C commercialized by Hayashibara Shoji, Inc., Okayama, Japan. The resulting solution was filtered in usual manner, and 25 ml aliquots of the filtrate were injected into plastic containers to obtain a solution containing glycosyl vitamin P.

[0040] The product, having an activity of supplementing vitamins, calories, and minerals, is used as a collyrium or injection for treating symptoms with asthenopia and/or heavy muscular rigidity.

Example 7

Cataplasm

[0041] One part by weight of crotamiton and 0.3 part by weight of " α G HESPERIDIN PS", a glycosyl hesperidin powder with a total hesperidin content of 80-84%, d.s.b., commercialized by Hayashibara Shoji, Inc., Okayama, Japan, were heated in water bath. While dissolving by mixing into a solution, 45.2 parts by weight of distilled water, 10 parts by weight of "TREHAOSE®", a crystalline trehalose powder commercialized by Hayashibara Shoji, Inc., Okayama, Japan, five parts by weight of gelatin, and seven parts by weight of kaolin were placed in a mixer and heated to about

50°C into a homogeneously dispersed solution. To the solution was added another dispersed solution of 25 parts by weight of glycerine, three parts by weight of sodium polyacrylate, and 3.5 parts by weight of carboxy methyl cellulose. The solution thus obtained was mixed while stirring to obtain a homogeneously-kneaded mixture.

5 [0042] The resulting product was added to the above dissolved solution and kneaded to homogeneity under stirring conditions. The newly obtained mixture was applied over a nonwoven fabric to form a film with one millimeter thick by using a spreader. After overlaying with a polypropylene sheet one side of the above fabric applied with the solution, the resulting fabric was cut in a prescribed size into the desired product.

10 [0043] The product gives substantially no unsatisfiable feeling when attached to the skin, and the effect lasts for a relatively-long period of time. Thus the product is useful as a cataplasma that relives muscular rigidity caused by lumbago, stiffness in the shoulder, muscular pains, etc., and that treats symptoms with muscular rigidity.

15 [0044] As described above, the present invention was made based on the self-finding that glycosyl vitamin P improves the blood circulation in humans to effectively relieve muscular rigidity. The present agent for improving the blood circulation exerts a remarkable effect on the recovery of mental and physical spirits from fatigue and treats/prevents diseases and symptoms such as stiffness in the shoulder, lumbagos, muscular pains, neuralgias, bruises, sprains, arthritis, neuritis, tendovaginitis, cervical spondylosis, thoracic outlet syndrome, asthenopia, feelings of cold, frostbites, arteriosclerosis, autonomic dystonia, and climacteric disturbance.

20 [0045] The present agent effectively acts on diseases induced by the disorder or the cease of blood circulation such as congestion, diminishes or extinctions the disorder or the cease of blood circulation where the advancement of diseases do not accompany blood coagulation or tissue necrosis, and effectively prevents circulatory diseases such as hypertension, arteriosclerosis, cerebral hemorrhage, cerebral thrombosis, cerebral embolism, subarachnoid hemorrhage, cerebral ischemia paroxysm, hypertensive encephalopathy, cerebral infarction, myocardial ischemia, myocardial infarction, and angina pectoris.

25 [0046] While there has been described what is at present considered to be the preferred embodiments of the invention, it will be understood the various modifications may be made therein, and it is intended to cover in the appended claims all such modifications as fall within the true spirits and scope of the invention.

Claims

- 30 1. An agent for improving the blood circulation which comprises glycosyl vitamin P as an effective ingredient.
2. An agent according to claim 1, wherein said glycosyl vitamin P is glycosyl hesperidin and/or glycosyl rutin.
3. An agent according to claim 1 or claim 2, which contains at least 0.001 w/w % of said glycosyl vitamin P.
- 35 4. An agent according to any one of claims 1 to 3, which further contains another ingredient that facilitates the administration of said glycosyl vitamin P.
5. An agent according to claim 4, wherein said another ingredient is a member selected from the group consisting of food materials, food ingredients, and pharmaceutically-acceptable carriers.
- 40 6. An agent according to any one of the preceding claims, which further comprises trehalose.
7. An agent according to claim 6, which contains said trehalose in an amount of five-fold higher than that of said glycosyl vitamin P, on a dry solid basis.
- 45 8. Use of glycosyl vitamin P for the preparation of a composition for improving blood circulation.
9. Use of an agent according to any one of claims 1 to 7, for the preparation of a muscular-rigidity lenitive composition.
- 50 10. Use according to claim 8 or claim 9, wherein the composition is orally or parenterally administered to a human.




FIG. 1




FIG. 2

THIS PAGE BLANK (USPTO)

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11)

EP 0 938 899 A3



(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
20.09.2000 Bulletin 2000/38

(51) Int Cl.7: A61K 31/70

(43) Date of publication A2:
01.09.1999 Bulletin 1999/35

(21) Application number: 98309544.9

(22) Date of filing: 23.11.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 09.12.1997 JP 35405997

(71) Applicant: KABUSHIKI KAISHA HAYASHIBARA
SEIBUTSU KAGAKU KENKYUJO
Okayama-shi Okayama (JP)

(72) Inventors:
• Fukuda, Shigeharu
Okayama-shi, Okayama (JP)
• Miyake, Toshio
Okayama-shi, Okayama (JP)

(74) Representative: Daniels, Jeffrey Nicholas et al
Page White & Farrer
54 Doughty Street
London WC1N 2LS (GB)

(54) Agent for improving the blood circulation

(57) An agent for improving the blood circulation, which contains as an effective ingredient glycosyl vita-

min P such as glycosyl hesperidin and glycosyl rutin. The agent improves the blood circulation in humans to effectively relieve muscular rigidity.

EP 0 938 899 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 98 30 9544
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
E	EP 0 922 460 A (HAYASHIBARA BIOCHEM LAB) 16 June 1999 (1999-06-16) * abstract * * page 3, line 46 - line 51 * * page 5, line 30 - line 39 * * page 5, line 55 - page 6, line 1 * * page 7, line 46 - line 51; claims *	1-7, 9, 10	A61K31/70
P, X	EP 0 868 916 A (HAYASHIBARA BIOCHEM LAB) 7 October 1998 (1998-10-07) * abstract * * page 3, line 43 - line 45 * * page 11, line 1 - line 21; table 4 * * examples A-4,B-1,B-2,B-9,B-10,B-23,B-24 * * claims *	1-7 — —/—	
TECHNICAL FIELDS SEARCHED (Int.Cl.6) A61K			
INCOMPLETE SEARCH The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims. Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search: see sheet C			
Place of search		Date of completion of the search	Examiner
THE HAGUE		31 July 2000	Hoff, P
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

European Patent
OfficeINCOMPLETE SEARCH
SHEET CApplication Number
EP 98 30 9544Claim(s) searched completely:
9Claim(s) searched incompletely:
1-8,10

Reason for the limitation of the search:

Present claims 1-8,10 relate to the treatment of an extremely large number of possible diseases. Support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the diseases to be treated. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the treatment of the diseases supported by pharmacological data (i.e. muscle rigidity, lumbago and stiffness in the shoulder) and to the general idea underlying the present invention (improvement of the blood circulation).



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 98 30 9544

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION
			TECHNICAL FIELDS SEARCHED
X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TATEFUJI, TOMOKI ET AL: "The effect of alpha.- glucosyl - hesperidin on heat loss from the limb skin surface determined by thermography" retrieved from STN Database accession no. 126:216421 XP002142196 * abstract * & FRAGRANCE J. (1997), 25(1), 91-97 , ----	1-5,8	
X	EP 0 461 827 A (HAYASHIBARA BIOCHEM LAB) 18 December 1991 (1991-12-18) * abstract * * page 2, line 55 - page 3, line 18 * * page 5, line 16 - line 18 * ----	1-5,8	
D,X	EP 0 402 049 A (HAYASHIBARA BIOCHEM LAB) 12 December 1990 (1990-12-12) * abstract * * page 2, line 1 - line 45 * * page 5, line 30 - line 35 * * page 5, line 41 - page 6, line 19; claims *	1-5	
Y	-----	8-10	
D,X	EP 0 420 376 A (HAYASHIBARA BIOCHEM LAB) 3 April 1991 (1991-04-03) * abstract * * page 2, line 1 - page 3, line 14 * * page 7, line 13 - line 33 * * page 8, line 32 - line 38; claims *	1-5	
Y	-----	8-10	
		-/-	

European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 98 30 9544

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D, X	EP 0 387 042 A (HAYASHIBARA BIOCHEM LAB) 12 September 1990 (1990-09-12) * abstract * * page 2, column 1, line 1 - column 2, line 2 * * page 6, column 10, line 2 - line 27 * * page 6, column 10, line 40 - line 53 * * page 7, column 12, line 23 - line 36 * * page 13, column 24, line 1 - line 47; claims *	1-5	
Y	FR 8 012 M (RECHERCHE ET THERAPEUTIQUE FRANCAISE NOUVELLE) 27 July 1970 (1970-07-27) * page 1, line 12 - line 16 * * page 2, line 1 - line 6 *	8-10	TECHNICAL FIELDS SEARCHED
Y	DATABASE WPI Section Ch, Week 198129 Derwent Publications Ltd., London, GB; Class B02, AN 1981-52839D XP002142197 & SU 681 841 A (AS USSR EVOLUTION BIOL), 7 March 1981 (1981-03-07) * abstract *	8,10	
Y	JELNES R ET AL: "Improvement of subcutaneous nutritional blood flow in the forefoot by hydroxyethylrutosides in patients with arterial insufficiency: case studies." ANGIOLOGY, (1986 MAR) 37 (3 PT 1) 198-202. XP000923173 * the whole document *	8,10	
		-/-	



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 98 30 9544

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	ALEY K O ET AL: "Anticatatonic effect of venoruton." METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, (1988 APR) 10 (4) 263-5. XP000923177 * the whole document *	9	
Y	EP 0 633 022 A (KUREHA CHEMICAL IND CO LTD) 11 January 1995 (1995-01-11) * abstract * * table 1, compound no.25,42 * * page 6, line 33 - line 35 * * page 9, line 15 - line 16; claims *	9	
X	J.E.F. REYNOLDS: "MARTINDALE, The Extra Pharmacopoeia" 1996, ROYAL PHARMACEUTICAL SOCIETY , LONDON XP002142195 * Bioflavonoids, page 1679 *	1-5	TECHNICAL FIELDS SEARCHED
X	EP 0 691 407 A (HAYASHIBARA BIOCHEM LAB) 10 January 1996 (1996-01-10) * examples B-16,B-17 *	1-7	

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 30 9544

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

31-07-2000

Patent document, cited in search report		Publication date		Patent family member(s)	Publication date
EP 0922460	A	16-06-1999	JP	11255655 A	21-09-1999
EP 0868916	A	07-10-1998	JP	11263795 A	28-09-1999
EP 0461827	A	18-12-1991	JP	2926432 B	28-07-1999
			JP	4046112 A	17-02-1992
			AT	158165 T	15-10-1997
			CA	2044317 A	12-12-1991
			DE	69127658 D	23-10-1997
			DE	69127658 T	12-03-1998
EP 0402049	A	12-12-1990	JP	3007593 A	14-01-1991
			AT	124996 T	15-07-1995
			CA	2018085 A	03-12-1990
			DE	69020810 D	17-08-1995
			DE	69020810 T	04-01-1996
			DK	402049 T	21-08-1995
			ES	2078308 T	16-12-1995
			GR	3017492 T	31-12-1995
			KR	153529 B	15-10-1998
			KR	184244 B	01-05-1999
			US	5627157 A	06-05-1997
			US	5652124 A	29-07-1997
EP 0420376	A	03-04-1991	JP	3115292 A	16-05-1991
			AT	135361 T	15-03-1996
			CA	2011617 A	28-03-1991
			DE	69025839 D	18-04-1996
			DE	69025839 T	14-11-1996
			KR	156539 B	15-10-1998
			US	5026833 A	25-06-1991
			US	5171573 A	15-12-1992
EP 0387042	A	12-09-1990	JP	2926411 B	28-07-1999
			JP	3027293 A	05-02-1991
			AT	118550 T	15-03-1995
			CA	2011618 A	08-09-1990
			DE	69016800 D	23-03-1995
			DE	69016800 T	20-07-1995
			DK	387042 T	03-04-1995
			ES	2071010 T	16-06-1995
			GR	3015814 T	31-07-1995
			KR	158454 B	16-11-1998
			KR	165956 B	01-02-1999
			KR	176956 B	01-04-1999
			US	5145781 A	08-09-1992

EPO FORM P0459
For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 30 9544

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

31-07-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0387042 A		JP 2000060484 A JP 3058790 A	29-02-2000 13-03-1991
FR 8012 M	27-07-1970	NONE	
SU 681841 A	07-03-1981	NONE	
EP 0633022 A	11-01-1995	JP 7025761 A AU 659579 B AU 6733994 A CA 2126513 A CN 1100633 A DE 69401763 D DE 69401763 T EP 0719554 A US 5650433 A	27-01-1995 18-05-1995 19-01-1995 10-01-1995 29-03-1995 27-03-1997 28-08-1997 03-07-1996 22-07-1997
EP 0691407 A	10-01-1996	JP 8073504 A CA 2152563 A US 5919668 A	19-03-1996 28-12-1995 06-07-1999

THIS PAGE BLANK (USPTO)